Woodline Partners »

Rapport Therapeutics shares owned by Woodline Partners

Quarter-by-quarter ownership of Rapport Therapeutics (RAPP) shares owned by Woodline Partners from 13F filings

Historical chart of Woodline Partners investment in Rapport Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapport Therapeutics held by Woodline Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapport Therapeutics by Woodline Partners

Quarter filed Position value Share count Share price at filing
2024-09-30 $3.8M 187k 20.48
2024-06-30 $4.0M 171k 23.26

More positions owned by Woodline Partners

Meta Platforms Cl A (META)
Gilead Sciences (GILD)
Abbvie (ABBV)
Revolution Medicines (RVMD)
Vaxcyte (PCVX)
Asml Holding N V N Y Registry Shs (ASML)
Nuvalent Inc-a (NUVL)
Permian Resources Corp Class A Com (PR)
Encana Corporation (OVV)
Keysight Technologies (KEYS)
Danaher Corporation (DHR)
Aon Shs Cl A (AON)
Stmicroelectronics N V Ny Registry (STM)
Regeneron Pharmaceuticals (REGN)
EQT Corporation (EQT)

View all positions for Woodline Partners

Top funds holding Rapport Therapeutics

Arch Venture Corp
Cormorant Asset Management
Capital Research and Management Company - Division 3
Johnson & Johnson
Sofinnova Ventures
T. Rowe Price Investment Management
Alliancebernstein
T. Rowe Price Associates
Perceptive Advisors
BlackRock
Citadel Advisors
Siren
Logos Global Management
Geode Capital Management
Woodline Partners

View all funds holding Rapport Therapeutics